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Abstract	
Pancreatic	neuroendocrine	neoplasms	(pNEN)	account	for	less	than	5%	of	all	pancreatic	
neoplasms	and	genetic	association	studies	on	susceptibility	to	the	disease	are	limited.	We	
sought	to	identify	possible	overlap	of	genetic	susceptibility	loci	between	pancreatic	ductal	
adenocarcinoma	(PDAC)	and	pNEN;	therefore,	PDAC	susceptibility	variants	(n=23)	from	
Caucasian	genome-wide	association	studies	(GWAS)	were	genotyped	in	369	pNEN	cases	and	
3,277	controls	from	the	PANcreatic	Disease	ReseArch	(PANDoRA)	consortium	to	evaluate	the	
odds	associated	with	pNEN	risk,	disease	onset	and	tumor	characteristics.	Main	effect	analyses	
showed	four	PDAC	susceptibility	variants	–	rs9854771,	rs1561927,	rs9543325	and	rs10919791	
to	be	associated	with	pNEN	risk.	Subsequently,	only	associations	with	rs9543325,	rs10919791	
and	rs1561927	were	noteworthy	with	false	positive	report	probability	(FPRP)	tests.	Stratified	
analyses	considering	age	at	onset	(50	year	threshold),	showed	rs2736098,	rs16986825	and	
rs9854771	to	be	associated	with	risk	of	developing	pNEN	at	a	younger	age.	Stratified	analyses	
also	showed	some	SNPs	to	be	associated	with	different	degrees	of	tumor	grade,	metastatic	
potential	and	functionality.	Our	results	identify	known	GWAS	PDAC	susceptibility	loci,	which	
may	also	be	involved	in	sporadic	pNEN	etiology	and	suggest	that	some	genetic	mechanisms	
governing	pathogenesis	of	these	two	entities	may	be	similar,	with	few	of	these	loci	being	more	
influential	in	younger	cases	or	tumor	subtypes.		
	
Summary:	This	study	identifies	an	overlap	of	susceptibility	loci	between	PDAC	and	pNEN	which	
may	provide	insights	on	potentially	useful	markers	for	risk	stratification	and	tumor	
characterization	among	healthy	individuals	and	pNEN	patients	respectively.	 	
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Introduction	
Pancreatic	neuroendocrine	neoplasms	(pNEN)	arise	from	islet	cells	and	comprise	less	than	5%	
of	all	new	pancreatic	neoplasms	(1).	Heterogeneous	in	tumor	behavior	and	clinical	symptoms,	
pNENs	account	for	10%	of	neuroendocrine	tumors	and	have	a	5-year	mortality	rate	of	60%	
(1,2).	Compared	to	the	more	common	exocrine	pancreatic	ductal	adenocarcinoma	(PDAC),	
pNENs	are	characterized	by	a	rather	‘silent’	clinical	course	and	generally	present	at	a	relatively	
earlier	age	(median	age	at	diagnosis	53	to	60	years,	and	72	years	for	PDAC)	(1).	Majority	(40-
90%)	of	pNENs	are	non-functional	(i.e.	do	not	secrete	hormones	that	cause	systemic	effects)	
thus	constituting	a	clinical	and	prognostic	challenge	for	physicians.	Surgical	resection	is	
currently	the	primary	curative	therapy	option	for	both	malignancies,	however,	most	patients	
unfortunately	exhibit	unresectable	tumors	at	diagnosis	(3),	stressing	the	need	for	improved	risk	
stratification	and	timely	diagnostic	biomarkers.	Familial	clustering	observed	in	population-
based	studies	among	PDAC	and	other	cancer	patients	provide	evidence	of	an	inherited	basis	for	
sporadic	pNEN	(1).	Although	there	is	no	clear	link	between	environmental	exposures	and	risk	of	
developing	pNEN,	an	overlap	of	risk	factors	in	PDAC	and	pNENs	is	likely	(4).	Increased	interest	in	
these	neoplasms	has	become	evident	in	the	last	decade,	but	despite	this,	molecular	
understanding	of	pNENs	is	still	insufficient	to	drive	clinical	interventions.	Recent	exome	and	
whole	genome	sequencing	studies	describing	the	genetic	basis	of	pNENs	among	Caucasians	
(5,6)	have	implicated	somatic	mutations	in	four	core	pathways:	activation	of	mTOR	signaling,	
DNA	damage	repair,	chromatin	modification	and	altered	telomere	length	in	tumorigenesis.	
Genome	wide	association	(GWAS)	or	candidate	gene	or	pathway	studies	investigating	the	
etiology	of	pNENs	have	been	reasonably	limited	by	small	sample	size,	when	compared	to	PDAC	
6	
	
	
	
for	which	23	common	risk	variants	have	so	far	been	identified	through	GWAS	or	studies	
focusing	on	genes	situated	in	well-known	pleiotropic	regions	(7–11).	Based	on	the	rationale	
that	known	common	genetic	susceptibility	loci	for	sporadic	PDAC	may	also	modify	the	risk	of	
developing	pNEN,	we	genotyped	369	pNEN	cases	from	a	retrospectively	enrolled	population	
within	the	PANDoRA	consortium	and	compared	genotype	frequencies	of	all	known	PDAC	GWAS	
susceptibility	variants	to	over	3,200	control	subjects	from	the	same	consortium.	We	tested	their	
possible	association	with	overall	sporadic	pNEN	risk	and	within	pNEN	subgroups.	
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Materials	and	methods	
Selection	of	subjects	and	polymorphisms:	Demographic	characteristics	subjects	within	the	
PANDoRA	consortium	have	been	described	previously	(12)	although	the	number	of	
neuroendocrine	cases	within	PANDoRA	has	increased	since	that	publication.	Written	informed	
consent	and	biospecimens	(blood,	tissue	or	genomic	DNA)	were	obtained	for	all	subjects	and	
ethical	approval	for	the	PANDoRA	study	protocol	received	from	the	Ethics	commission	of	the	
Medical	Faculty	Heidelberg.	Only	sporadic	(non-familial)	pNEN	cases	not	associated	with	
genetic	syndromes	such	as	multiple	endocrine	neoplasia	type	1	(MEN-1),	von	Hippel-Lindau	
syndrome	(VHL),	von	Recklinghausen	disease	(neurofibromatosis	NF-1),	and	tuberous	sclerosis	
complex	(TSC)	were	used	in	this	study.	Twenty-three	(23)	single	nucleotide	polymorphisms	
(SNPs)	reaching	genome-wide	significance	and	suggestive	levels	(up	to	5	x	10-7)	were	selected	
from	GWAS	publications	in	PDAC	among	Caucasians	(7–10).	pNEN	tumors	were	classified	
according	to	the	World	Health	Organization	2010	classification	system	(13).			
	
Genotyping	and	quality	control:	SNPs	were	genotyped	in	369	pNEN	cases	and	3,277	controls	
using	TaqMan	allelic	discrimination	(Applied	Biosystems)	and	KASPar	(LGC	Genomics)	assays	
according	to	manufacturers’	instructions.	Post-PCR	allelic	discrimination	was	done	on	the	
7900HT	Real-Time	PCR	system	(Life	Technologies)	and	data	analyzed	using	the	affiliated	SDS	
software	(v.2.3).	Internal	replicates	(7%	of	all	samples)	and	negative	controls	were	included	to	
assess	the	fidelity	of	genotype	calls.	Deviation	from	Hardy	Weinberg	equilibrium	(HWE)	was	
checked	using	the	Pearson’s	χ2	test.	
	
8	
	
	
	
Statistical	analyses:	We	evaluated	associations	(odds	ratios	(OR)	and	95%	confidence	intervals	
(CI))	between	SNPs	and	pNEN	risk	using	unconditional	multivariate	logistic	regression	in	STATA	
v.11	(StataCorp	LP).	Tests	were	done	using	a	codominant	inheritance	model,	with	adjustment	
for	potential	confounding	variables	-	age,	geographical	origin	and	gender.	We	used	a	nominal	
significance	threshold	(p<0.05)	since	the	selected	SNPs	were	based	on	prior	evidence	of	their	
association	with	pancreatic	cancer.	Noteworthiness	of	SNP	associations	with	p<0.05	were	
tested	using	the	Bayesian	false	positive	report	probability	(FPRP)	test	which	takes	the	observed	
P-value,	statistical	power	of	the	test,	and	prior	probabilities	for	the	associations	into	account	
(14).	All	selected	SNPs	bore	a	high	prior	possibility	of	being	associated	with	pNEN	risk	(π	=	0.2)	
as	recommended	by	Wacholder	and	colleagues	(14),	and	only	SNP	associations	with	p<0.05	and	
π<0.2	were	considered	‘noteworthy’.	To	evaluate	the	effect	of	SNPs	on	pNEN	onset,	we	first	
performed	a	case-only	analysis	comparing	genotype	distributions	among	cases	(>50	years)	with	
their	younger	counterparts	(≤50	years)	while	adjusting	for	gender	and	geographical	origin.	We	
also	compared	genetic	associations	from	three	additional	models:	cases	≤50	years	versus	
controls	of	all	ages	(EOP1),	cases	>50	years	versus	controls	of	all	ages	(TOP),	and	cases	up	to	50	
years	versus	controls	up	to	50	years	(EOP2).	Associations	between	SNPs	and	tumor	grade	and	
stage	were	estimated	by	case-only	analyses.	For	tumor	stage,	we	compared	stage	IV	tumors	
versus	all	other	tumors	(stage	I,	IIa,	IIb,	IIIa,	IIIb)	based	on	European	Neuroendocrine	Tumor	
Society	(ENETS)	classification	system	(15)	and	for	grade,	we	compared	well	differentiated	
tumors	(grade	1	and	2)	versus	poorly	differentiated	tumors	(grade	3)	based	on	the	World	
Health	Organization	(WHO)/ENETS	guidelines	(16).	Tumor	functional	status	(e.g.	insulinoma,	
gastrinomas,	etc)	was	available	for	54%	of	all	cases	in	this	study,	out	of	which	62%	were	non-
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functioning.	We	compared	genotype	frequencies	of	all	SNPs	in	the	latter	with	functioning	
tumors.		
	
Microarray	data	screening:	To	gain	additional	insight	to	the	transcriptomic	profiles	of	these	
gene	regions	in	human	pancreatic	islet	cells,	we	explored	expression	profiling	data	from	the	
Gene	Expression	Omnibus	(GEO)	database	(Accession	number	GSE43795);	this	study	
characterized	mRNA	and	microRNA	expression	profiles	in	solid-pseudopapillary	neoplasms	of	
pancreas	(n=14),	ductal	adenocarcinoma	(n=6),	pancreatic	neuroendocrine	tumors	(n=6)	and	
non-neoplastic	pancreatic	tissue	samples	(n=5)	(17).	Results	were	downloaded	in	text	format	
and	GEO2R	queries	(http://www.ncbi.nlm.nih.gov/geo/geo2r/)	applied	to	assess	differentially-
expressed	genes	in	pNEN	compared	to	non-neoplastic	pancreas	tissue	samples.	GEO2R	is	an	R	
programming	language-based	dataset	analysis	tool	that	compares	two	or	more	groups	of	
samples	under	the	same	experimental	conditions	and	analyzes	almost	any	GEO	series	(18).	P	
values	were	adjusted	to	correct	for	false-positives	due	to	multiple	testing	using	Benjamini	and	
Hochberg	false	discovery	rate	method	and	genes	that	met	the	cut-off	criteria	of	Padjusted	<	0.05	
and	|logFC|	>	1.0	were	screened	out	as	differentially-expressed	genes.	
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Results	
Baseline	characteristics	of	the	study	population	are	summarized	in	table	I.	The	median	age	at	
diagnosis	in	this	study	was	57	years,	congruent	with	previous	literature	reports.	Genotypes	for	
most	SNPs,	except	rs505922	(P	=	0.04)	were	distributed	in	accordance	to	Hardy-Weinberg	
equilibrium	(HWE)	among	controls.	Duplicated	samples	showed	genotyping	concordance	rate	
of	99.6%.	Genotyping	data	for	those	subjects	with	genotyping	completion	rates	below	75%	(n	=	
35)	were	excluded	from	all	statistical	analyses.		
	
Overall	pNEN	risk	analyses:		Minor	allele	frequencies,	genotype	distributions,	risk	estimates	
(odds	ratios	(OR)	and	95%	confidence	intervals	(CI))	of	all	polymorphisms	investigated	in	this	
study	are	summarized	in	table	II.	rs9543325	was	associated	with	higher	risk	of	pNEN	(OR	1.63,	
95%	CI	(1.10-2.47),	Phom	=	0.02).	rs10919791,	rs1561927	and	rs9854771	were	associated	with	
lower	risk	of	pNEN	(OR	0.65,	95%	CI	(0.46-0.93),	Phet	=	0.02;	OR	0.71,	95%	CI	(0.55-0.92),	Phet	=	
0.01	and	OR	0.76,	95%	CI	(0.58-0.99),	Phet	=	0.04	respectively).	Subsequent	testing	of	these	
findings	using	false	positive	report	probability	(FPRP)	with	a	prior	of	0.2	showed	that	only	
associations	with	rs10919791	(FPRP	=	0.13),	rs9543325	(FPRP	=	0.15)	and	rs1561927	(FPRP	=	
0.07)	were	noteworthy.	The	association	with	rs9854771	failed	the	noteworthiness	test	(FPRP	=	
0.25).	
	
Stratified	analyses	based	on	age	at	pNEN	onset:	With	stratification	according	to	age	at	disease	
onset	(≤50	years	vs.	>50	years)	among	successfully	genotyped	pNEN	cases,	we	observed	
significant	differences	between	genotype	groups	for	rs16986825	(ZNRF)	(OR	2.67,	95%	CI	(1.57-
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4.55),	Phet	=	0.0003	and	OR	2.27,	95%	CI	(1.37-3.77),	P	=	0.002	in	the	recessive	model);	
rs2736098	(TERT)	(OR	3.71,	95%	CI	(1.36-10.10),	Phom	=	0.01;	and	rs9854771	(TP63)	(OR	1.85,	
95%	CI	(1.11-3.10),	Phet	=	0.02	and	OR	1.69	,	95%	CI	(1.04-2.75),	P	=	0.03	in	the	recessive	model	
(table	III).	FPRP	tests	were	similarly	applied	using	a	prior	probability	of	0.2	and	associations	
between	early	pNEN	onset	and	rs16986825	(FPRP	<	0.01	in	both	models),	rs2736098	(FPRP	=	
0.08),	and	rs9854771	(FPRP	=	0.14),	were	noteworthy.	For	rs9854771,	our	observed	association	
for	the	recessive	model	was	not	noteworthy	(FPRP	=	0.22).	Since	pNENs	are	diagnosed	roughly	
10	years	earlier	than	PDAC,	we	also	performed	the	same	stratified	analyses	with	threshold	at	40	
years,	and	only	the	TERT	SNPs	(rs2736098	and	rs2853677)	were	significantly	associated	with	
higher	risk	of	developing	pNEN	at	40	years	or	younger,	albeit	with	extremely	small	group	sizes	
(results	not	shown).	Results	from	alternative	analyses	of	disease	onset	using	three	additional	
models:	cases	≤50	years	versus	controls	of	all	ages	(EOP1),	cases	>50	years	versus	controls	of	all	
ages	(TOP),	and	cases	up	to	50	years	versus	controls	up	to	50	years	(EOP2)	are	shown	in	
supplementary	table	I.		
	
Stratified	analyses	based	on	tumor	characteristics	(grade,	stage	and	functional	status):	With	
stratification	based	on	disease	grade,	rs10919791	and	rs16986825	were	associated	with	well	
differentiated	pNEN	tumors	(OR	5.11,	95%	CI	(1.13	-	23.14),	P	=	0.03	and	OR	7.44,	95%	CI	(1.09	-	
50.5),	P	=	0.04	respectively).	rs1561927,	rs9854771	and	rs351365	were	also	associated	with	
tumors	with	nodal	metastasis	(i.e.	advanced	stage)	(OR	2.39,	95%	CI	(1.18	-	4.85),	P	=	0.02;	OR	
0.46,	95%	CI	(0.24	-	0.88),	P	=	0.02;	and	OR	4.62,	95%	CI	(1.16	-	18.38),	P	=	0.03)	respectively.	
However,	only	the	association	between	rs9854771	and	stage	appeared	reliable,	considering	
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that	the	size	of	genotype	groups	was	much	smaller	for	other	SNPs.	FPRP	tests	applied	using	a	
prior	probability	of	0.2	showed	the	association	between	tumor	grade	and	rs10919791	(FPRP	=	
0.19)	to	be	noteworthy.	For	rs16986825,	the	association	was	not	noteworthy	(FPRP	>	0.20).	
Regarding	tumor	stage,	associations	with	rs1561927,	rs9854771	and	rs351365	(recessive	model	
only)	(FPRP=0.11,	0.16	and	0.19	respectively)	were	noteworthy.	Two	variants	rs7310409	
(HNF1A)	and	rs1517037	(GRP)	also	appeared	to	be	associated	with	tumor	functional	status	(OR	
0.36,	95%	CI	(0.16-0.79),	P	=	0.01	and	OR	0.37,	95%	CI	(0.16-0.85),	P	=	0.02	respectively	(table	
III).	Both	associations	were	noteworthy	at	the	0.2	threshold	(FPRP	<	0.08).	Associations	
between	all	23	SNPs	and	tumor	characteristics	are	shown	in	supplementary	table	II.		
	
Differentially-expressed	genes	based	on	microarray	data	screening:	Reasoning	that	the	
additional	gene	expression	profiles	of	all	26	genes	harboring	or	located	close	to	the	SNPs	
investigated	in	this	study	would	amplify	our	ability	to	identify	relevant	underlying	biological	
processes,	we	screened	a	GEO	superseries	dataset	including	6	pNEN,	5	healthy	pancreas	
(controls)	and	6	ductal	adenocarcinoma	tissue	samples.	Based	on	the	inclusion	criteria	of	
Padjusted	<	0.05	and	|logFC|	>	1.0,	five	of	these	genes	–	nuclear	receptor	subfamily	5	group	A	
member	2	(NR5A2),	v-myc	avian	myelocytomatosis	viral	oncogene	homolog	(MYC),	Krüppel-like	
factor	(KLF)	5	(KLF5)	and	chymotrypsinogen	genes,	CTRB1	and	CTRB2	were	under	expressed	in	
pNEN	compared	to	normal	pancreas	tissue	(table	V).	Supplementary	table	III	shows	expression	
data	for	all	23	SNPs.	Our	analyses	are	based	on	only	a	few	samples,	therefore	caution	should	be	
applied	in	the	interpretation	of	these	results.	
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Discussion	
By	investigating	known	GWAS	PDAC	susceptibility	loci	(MAF≥5%),	our	study	has	identified	the	
possible	role	of	these	loci	in	the	risk	of	developing	pNEN.	Combined	with	gene	expression	
analyses,	we	report	for	the	first	time,	few	loci	which	may	also	be	involved	in	genetic	
mechanisms	influencing	pNEN	tumorigenesis,	age	at	onset	and	tumor	characteristics.	These	
findings	confirm	that	some	susceptibility	loci	are	shared	by	both	entities.	Interestingly,	most	
known	environmental	risk	factors	associated	with	increased	pNEN	risk	are	also	associated	with	
PDAC	risk	(4).	Although	rarity	and	lack	of	predictive	biomarkers	for	early-stage	diagnosis	or	risk	
stratification	of	healthy	individuals	in	both	entities	are	two	common	features	of	these	
neoplasms,	understanding	their	molecular	mechanisms	remains	essential	and	advantageous.	It	
is	common	albeit	controversial	knowledge	that	pancreatic	ductal	cells	are	‘potential	facultative	
stem	cells’	capable	of	being	reprogrammed	into	cells	that	closely	resemble	islet	cells	in	vivo	
(19,20).	Whether	the	shared	genetic	susceptibility	is	due	to	the	origin	of	both	these	tumor	
types	from	a	common	pluripotent	precursor	cell,	or	a	phenomenon	linked	with	the	reported	
capacity	of	islet	cells	to	transdifferentiate	to	ductal	cells	(21,22)	is	currently	unknown.	Among	
explanations	proposed	for	the	transdifferentiation	of	pancreas	cells,	a	largely	favored	one	in	
pathogenesis	is	based	on	the	hypothesis	that	tumor	stroma	mimics	the	regulatory	role	of	
pancreatic	embryonic	mesenchyme	in	duct	and	endocrine	development,	to	induce	the	switch	
between	ductules	and	endocrine	cells	(23,24).	A	second	hypothesis	based	on	multiple	lines	of	
evidence	also	suggests	that	tumor	cells	may	originate	from	a	common	pluripotent	cell	which	
matures	into	two	phenotypically	different	cell	lines	(25),	and	this	pluripotent	cell	expresses	
transcription	factors	such	as	PDX1	and	SOX9	which	are	involved	in	pancreatic	development	and	
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homeostasis	(26).	Our	study,	which	comprised	of	369	pNEN	cases	and	3,277	healthy	controls	
from	the	international	PANDoRA	consortium,	represents	the	largest	of	such	studies	performed	
to	date.	Recent	attempts	to	delineate	the	mutational	landscape	of	pNENs	through	whole	
genome	sequencing	(6),	have	implicated	activation	of	mTOR	signaling	as	one	of	the	core	
pathways	commonly	altered	in	these	neoplasms.		
In	overall	risk	analyses,	four	SNPs	(rs9854771,	rs9543325,	rs1561927	and	rs10919791)	showed	
associations	with	sporadic	pNEN	at	p<0.05.	Adjustment	for	multiple	comparisons	was	not	
applied	to	the	nominal	significance	threshold	(p<0.05)	since	selected	SNPs	were	based	on	prior	
evidence	of	their	association	with	pancreatic	cancer.	Using	the	FPRP	model	in	overall	analyses,	
only	associations	with	rs10919791,	rs9543325	and	rs1561927	reached	noteworthiness	with	a	
prior	probability	of	0.2.	
rs1561927	in	MIR1208/PVT1	was	associated	with	a	29%	lower	risk	of	developing	pNEN	among	
heterozygotes,	which	is	similar	to	the	original	report	in	PDACs	(allelic	OR	0.87	95%	CI	(0.83–
0.92)	(9)).	This	intronic	SNP	maps	to	a	locus	associated	with	suggested	long-distance	
interactions	with	MYC	and	PVT1	promoters	in	multiple	cancers	(9).	rs9543325,	an	intergenic	
SNP	in	chr13q22.1	which	is	frequently	deleted	in	several	cancers	(8)	was	associated	with	a	37%	
increased	risk	of	developing	pNEN	(for	subjects	with	CC	genotype),	higher	than	risk	estimates	
from	the	original	study	in	PDACs	(OR	1.26	95%	CI	(1.18–1.35)	(8).	Genes	closest	to	this	locus	are	
KLF5,	KLF12,	PIBF1,	DIS3	and	BORA,	which	range	up	to	586kb	in	distance	from	rs9543325.	
Krüppel-like	factor	(KLF)	5	and	12	are	members	of	a	family	of	zinc-finger	transcription	factors	
reported	to	exhibit	tumor-suppressor	and	oncogenic	activity	respectively	in	various	human	
cancers	(27).	KLF5	is	involved	in	transcriptional	activation	of	PI3K/Akt	signaling,	BORA	(encoding	
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aurora	kinase	A	activator)	is	known	to	regulate	cell	proliferation	and	overexpressed	in	tumors	
(28).	PIBF1	(encoding	progesterone	immunomodulatory	binding	factor	1)	is	speculated	to	be	
involved	in	progesterone-dependent	immunomodulation	with	higher	levels	in	tumors	(28).	
Aberrant	expression	of	DIS3	has	been	implicated	in	many	cancers	and	plays	a	crucial	role	in	
gene	regulation	and	small	RNA	processing	(29).	rs10919791	lies	in	the	first	intron	of	NR5A2	
(chr1q32.1)	which	plays	crucial	roles	in	pancreatic	function	and	development	(30).	In	the	
current	study,	rs10919791	was	associated	with	a	35%	lower	risk	of	developing	pNEN	among	
heterozygotes,	similar	to	the	original	estimate	among	PDACs	(ORhet	0.76	(0.68–0.84))	(8).		
The	bioinformatics	approach	with	a	GEO2R	microarray	dataset	including	pancreatic	
neuroendocrine	tumors	(n=6)	and	non-neoplastic	pancreatic	tissue	samples	(n=5),	was	used	to	
augment	results	from	our	study	and	explore	the	plausible	role	of	these	genes	in	pNEN	
development.	Interestingly,	MYC,	KLF5,	NR5A2,	CTRB1	and	CTRB2	appeared	down-regulated	
among	pNENs	compared	to	non-neoplastic	pancreatic	tissue	in	the	microarray	dataset,	further	
implicating	these	genes	in	pNEN	tumorigenesis.	To	substantiate	these	findings,	we	performed	a	
similar	comparison	of	expression	profiles	of	these	genes	in	PDAC	(n=6)	versus	healthy	pancreas,	
which	showed	differential	expression	of	all	genes	but	KLF5	in	the	same	manner.		To	the	best	of	
our	knowledge	this	is	the	only	publicly	available	dataset	that	includes	expression	data	of	pNEN.	
The	data	we	observed	in	this	dataset	corroborate	our	findings	of	the	association	analysis.	
Nevertheless	the	very	small	sample	size	of	this	dataset	is	a	cause	for	concern,	and	these	data	
should	be	taken	with	caution.	
Additional	stratified	analyses	based	on	age	at	onset	and	tumor	characteristics	(tables	III	and	IV	
respectively),	despite	relatively	small	genotype	strata	for	some	SNPs,	also	shed	light	on	
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susceptibility	loci	that	may	be	useful	for	improved	risk	stratification	and	possible	choice	of	
therapy	based	on	tumor	characteristics.	The	contribution	of	rs7310409	to	pNEN	development	is	
conceivable	given	that	pleiotropic	HNF1A	plays	a	crucial	role,	as	a	tumor	suppressor,	in	the	
transcriptional	regulation	in	endocrine	and	exocrine	pancreas	development	and	homeostasis	
(31).	This	locus	has	also	been	reported	as	a	prime	candidate	mediating	susceptibility	to	type	2	
diabetes	among	Caucasians	(32).	Although	the	role	of	p53	homolog,	p63	in	pancreatic	cancer	is	
poorly	understood,	it	has	been	implicated	in	tumorigenesis	and	metastasis	via	cell	cycle	arrest	
and	apoptotic	mechanisms	(33).	Our	observed	association	between	heterozygous	carriers	of	
this	polymorphism	and	metastatic	pNEN	tumors	is	therefore	plausible.		
Nevertheless,	the	small	size	observed	in	each	stratum	due	to	the	rarity	of	these	neoplasms,	
raises	a	valid	concern	on	the	possible	interpretation	of	our	findings.	We	therefore	applied	the	
FPRP	approach	instead	of	a	much	lower	P	value	adjusted	for	multiple	comparisons,	as	the	latter	
would	have	resulted	in	unnecessarily	low	power	for	our	high	prior	probability	hypotheses,	
particularly	in	these	neoplasms	where	collection	of	larger	number	of	cases	is	unrealistic.	
Notwithstanding,	all	noteworthy	findings	reported	here	must	be	interpreted	with	caution	and	
replicated	in	possibly	larger	and	independent	studies.	
The	major	strengths	of	this	study	are	its	relatively	large	size,	considering	the	low	incidence	of	
pNEN,	and	data	analysis	approaches	applied	to	minimize	the	effect	of	potentially	confounding	
factors	and	more	importantly	evaluate	the	noteworthiness	of	our	findings.	The	integration	of	
gene	expression	profiling	provides	valuable	insight	to	shared	genetic	correlations	and	expands	
the	probable	margins	of	our	results.	A	limitation	of	our	investigations	however,	was	that	due	to	
17	
	
	
	
lack	of	clinical	information,	we	could	not	stratify	subjects	based	on	familial	history	of	PDAC	or	
other	non-genetic	factors	such	as	history	of	diabetes	mellitus.		
Taken	together,	these	results	illuminate	genetic	similarities	between	the	two	main	groups	of	
pancreatic	neoplasms,	suggesting	that	common	variations	at	three	known	PDAC	susceptibility	
loci	–	13q22.1	(TP63,	rs9543325),	1q32.1	(NR5A2,	rs10919791)	and	8q24.21	(MIR1208/PVT1,	
rs1561927)	potentially	influence	tumorigenesis	of	pancreatic	beta	cells	in	a	similar	manner	as	in	
exocrine	pancreatic	cells.	Our	results	also	suggest	that	genetic	predisposing	factors	vary	on	the	
basis	of	age	at	pNEN	onset	as	well	as	tumor	characteristics.	Striking	similarities	between	
embryogenesis	and	tumorigenesis	which	have	become	more	apparent	in	past	decades	taken	
together	with	our	genetic	findings	may	provide	groundwork	for	future	evaluation	of	the	
potential	usability	of	these	loci	as	predictive	biomarkers	and	in	risk	assessment.	Functional	
studies	are	also	warranted	to	better	understand	the	biological	implications	of	these	loci	in	
pancreatic	hormone-producing	(endocrine)	and	enzyme-producing	(exocrine)	cell	function.	
	
Acknowledgement	
The	authors	acknowledge	Angelika	Stein	(DKFZ,	Heidelberg,	Germany)	for	her	technical	support.		
	
Author	contributions	
Conception	and	design:	D.C,	F.C	and	O.O.		
Acquisition	of	samples	and	clinical	data:	All	authors.		
Analysis	and	interpretation	of	data	(e.g.,	experimental	and	statistical	analysis):	O.O,	D.C	and	
F.C		
18	
	
	
	
Writing,	review,	and/or	revision	of	the	manuscript:	O.O,	G.C,	D.C,	F.C.	and	all	other	authors	
contributed	to	its	critical	revision.	
	
	 	
19	
	
	
	
References	
1.		 Capurso	G,	Falconi	M,	Panzuto	F,	Rinzivillo	M,	Boninsegna	L,	Bettini	R,	et	al.	Risk	factors	for	
sporadic	pancreatic	endocrine	tumors:	a	case-control	study	of	prospectively	evaluated	
patients.	Am	J	Gastroenterol.	2009	Dec;104(12):3034–41.		
2.		 Yao	JC,	Hassan	M,	Phan	A,	Dagohoy	C,	Leary	C,	Mares	JE,	et	al.	One	Hundred	Years	After	
“Carcinoid”:	Epidemiology	of	and	Prognostic	Factors	for	Neuroendocrine	Tumors	in	35,825	
Cases	in	the	United	States.	J	Clin	Oncol.	2008	Jun	20;26(18):3063–72.		
3.		 Li	D,	Xie	K,	Wolff	R,	Abbruzzese	JL.	Pancreatic	cancer.	Lancet	Lond	Engl.	2004	Mar	
27;363(9414):1049–57.		
4.		 Haugvik	S-P,	Hedenström	P,	Korsæth	E,	Valente	R,	Hayes	A,	Siuka	D,	et	al.	Diabetes,	
smoking,	alcohol	use,	and	family	history	of	cancer	as	risk	factors	for	pancreatic	
neuroendocrine	tumors:	a	systematic	review	and	meta-analysis.	Neuroendocrinology.	
2015;101(2):133–42.		
5.		 Jiao	Y,	Shi	C,	Edil	BH,	de	Wilde	RF,	Klimstra	DS,	Maitra	A,	et	al.	DAXX/ATRX,	MEN1,	and	
mTOR	pathway	genes	are	frequently	altered	in	pancreatic	neuroendocrine	tumors.	
Science.	2011	Mar	4;331(6021):1199–203.		
6.		 Scarpa	A,	Chang	DK,	Nones	K,	Corbo	V,	Patch	A-M,	Bailey	P,	et	al.	Whole-genome	
landscape	of	pancreatic	neuroendocrine	tumours.	Nature.	2017	Mar	2;543(7643):65–71.		
7.		 Amundadottir	L,	Kraft	P,	Stolzenberg-Solomon	RZ,	Fuchs	CS,	Petersen	GM,	Arslan	AA,	et	al.	
Genome-wide	association	study	identifies	variants	in	the	ABO	locus	associated	with	
susceptibility	to	pancreatic	cancer.	Nat	Genet.	2009	Sep;41(9):986–90.		
8.		 Petersen	GM,	Amundadottir	L,	Fuchs	CS,	Kraft	P,	Stolzenberg-Solomon	RZ,	Jacobs	KB,	et	al.	
A	genome-wide	association	study	identifies	pancreatic	cancer	susceptibility	loci	on	
chromosomes	13q22.1,	1q32.1	and	5p15.33.	Nat	Genet.	2010	Mar;42(3):224–8.		
9.		 Wolpin	BM,	Rizzato	C,	Kraft	P,	Kooperberg	C,	Petersen	GM,	Wang	Z,	et	al.	Genome-wide	
association	study	identifies	multiple	susceptibility	loci	for	pancreatic	cancer.	Nat	Genet.	
2014	Sep;46(9):994–1000.		
10.		 Childs	EJ,	Mocci	E,	Campa	D,	Bracci	PM,	Gallinger	S,	Goggins	M,	et	al.	Common	variation	at	
2p13.3,	3q29,	7p13	and	17q25.1	associated	with	susceptibility	to	pancreatic	cancer.	Nat	
Genet.	2015	Aug;47(8):911–6.		
11.		 Campa	D,	Rizzato	C,	Stolzenberg-Solomon	R,	Pacetti	P,	Vodicka	P,	Cleary	SP,	et	al.	TERT	
gene	harbors	multiple	variants	associated	with	pancreatic	cancer	susceptibility.	Int	J	
Cancer.	2015	Nov	1;137(9):2175–83.		
20	
	
	
	
12.		 Campa	D,	Rizzato	C,	Capurso	G,	Giese	N,	Funel	N,	Greenhalf	W,	et	al.	Genetic	susceptibility	
to	pancreatic	cancer	and	its	functional	characterisation:	the	PANcreatic	Disease	ReseArch	
(PANDoRA)	consortium.	Dig	Liver	Dis	Off	J	Ital	Soc	Gastroenterol	Ital	Assoc	Study	Liver.	
2013	Feb;45(2):95–9.		
13.		 Bosman,	Carneiro,	Hruban,	Theise.	WHO	Classification	of	Tumours	of	the	Digestive	
System.	4th	ed.	World	Health	Organization	ISBN:	978-92-832-2432-7;	2010.	417	p.		
14.		 Wacholder	S,	Chanock	S,	Garcia-Closas	M,	Ghormli	LE,	Rothman	N.	Assessing	the	
Probability	That	a	Positive	Report	is	False:	An	Approach	for	Molecular	Epidemiology	
Studies.	J	Natl	Cancer	Inst.	2004	Mar	17;96(6):434–42.		
15.		 Ramage	JK,	Ahmed	A,	Ardill	J,	Bax	N,	Breen	DJ,	Caplin	ME,	et	al.	Guidelines	for	the	
management	of	gastroenteropancreatic	neuroendocrine	(including	carcinoid)	tumours	
(NETs).	Gut.	2012	Jan	1;61(1):6–32.		
16.		 Klimstra	DS,	Modlin	IR,	Coppola	D,	Lloyd	RV,	Suster	S.	The	pathologic	classification	of	
neuroendocrine	tumors:	a	review	of	nomenclature,	grading,	and	staging	systems.	
Pancreas.	2010	Aug;39(6):707–12.		
17.		 Park	M,	Kim	M,	Hwang	D,	Park	M,	Kim	WK,	Kim	SK,	et	al.	Characterization	of	gene	
expression	and	activated	signaling	pathways	in	solid-pseudopapillary	neoplasm	of	
pancreas.	Mod	Pathol	Off	J	U	S	Can	Acad	Pathol	Inc.	2014	Apr;27(4):580–93.		
18.		 Barrett	T,	Wilhite	SE,	Ledoux	P,	Evangelista	C,	Kim	IF,	Tomashevsky	M,	et	al.	NCBI	GEO:	
archive	for	functional	genomics	data	sets--update.	Nucleic	Acids	Res.	2013	
Jan;41(Database	issue):D991-995.		
19.		 Zhou	Q,	Brown	J,	Kanarek	A,	Rajagopal	J,	Melton	DA.	In	vivo	reprogramming	of	adult	
pancreatic	exocrine	cells	to	beta-cells.	Nature.	2008	Oct	2;455(7213):627–32.		
20.		 Hezel	AF,	Kimmelman	AC,	Stanger	BZ,	Bardeesy	N,	DePinho	RA.	Genetics	and	biology	of	
pancreatic	ductal	adenocarcinoma.	Genes	Dev.	2006	May	15;20(10):1218–49.		
21.		 Pour	PM,	Pandey	KK,	Batra	SK.	What	is	the	origin	of	pancreatic	adenocarcinoma?	Mol	
Cancer.	2003	Jan	22;2:13.		
22.		 Maitra	A,	Leach	SD.	Disputed	paternity:	the	uncertain	ancestry	of	pancreatic	ductal	
neoplasia.	Cancer	Cell.	2012	Dec	11;22(6):701–3.		
23.		 Deshpande	V,	Selig	MK,	Nielsen	GP,	Fernandez-del	Castillo	C,	Lauwers	GY.	Ductulo-insular	
pancreatic	endocrine	neoplasms:	clinicopathologic	analysis	of	a	unique	subtype	of	
pancreatic	endocrine	neoplasms.	Am	J	Surg	Pathol.	2003	Apr;27(4):461–8.		
21	
	
	
	
24.		 Landsman	L,	Nijagal	A,	Whitchurch	TJ,	Vanderlaan	RL,	Zimmer	WE,	Mackenzie	TC,	et	al.	
Pancreatic	mesenchyme	regulates	epithelial	organogenesis	throughout	development.	
PLoS	Biol.	2011	Sep;9(9):e1001143.		
25.		 Regitnig	P,	Spuller	E,	Denk	H.	Insulinoma	of	the	pancreas	with	insular-ductular	
differentiation	in	its	liver	metastasis--indication	of	a	common	stem-cell	origin	of	the	
exocrine	and	endocrine	components.	Virchows	Arch	Int	J	Pathol.	2001	Jun;438(6):624–8.		
26.		 Oliver-Krasinski	JM,	Kasner	MT,	Yang	J,	Crutchlow	MF,	Rustgi	AK,	Kaestner	KH,	et	al.	The	
diabetes	gene	Pdx1	regulates	the	transcriptional	network	of	pancreatic	endocrine	
progenitor	cells	in	mice.	J	Clin	Invest.	2009	Jul;119(7):1888–98.		
27.		 McConnell	BB,	Yang	VW.	Mammalian	Krüppel-Like	Factors	in	Health	and	Diseases.	Physiol	
Rev.	2010	Oct	1;90(4):1337–81.		
28.		 Azmi	A.	Molecular	Diagnostics	and	Treatment	of	Pancreatic	Cancer:	Systems	and	Network	
Biology	Approaches.	Elsevier;	2014.	467	p.		
29.		 Robinson	SR,	Oliver	AW,	Chevassut	TJ,	Newbury	SF.	The	3’	to	5’	Exoribonuclease	DIS3:	
From	Structure	and	Mechanisms	to	Biological	Functions	and	Role	in	Human	Disease.	
Biomolecules.	2015	Jul	17;5(3):1515–39.		
30.		 Kelly	VR,	Xu	B,	Kuick	R,	Koenig	RJ,	Hammer	GD.	Dax1	up-regulates	Oct4	expression	in	
mouse	embryonic	stem	cells	via	LRH-1	and	SRA.	Mol	Endocrinol	Baltim	Md.	2010	
Dec;24(12):2281–91.		
31.		 Hoskins	JW,	Jia	J,	Flandez	M,	Parikh	H,	Xiao	W,	Collins	I,	et	al.	Transcriptome	analysis	of	
pancreatic	cancer	reveals	a	tumor	suppressor	function	for	HNF1A.	Carcinogenesis.	2014	
Dec;35(12):2670–8.		
32.		 Voight	BF,	Scott	LJ,	Steinthorsdottir	V,	Morris	AP,	Dina	C,	Welch	RP,	et	al.	Twelve	type	2	
diabetes	susceptibility	loci	identified	through	large-scale	association	analysis.	Nat	Genet.	
2010	Jul;42(7):579–89.		
33.		 Bergholz	J,	Xiao	Z-X.	Role	of	p63	in	Development,	Tumorigenesis	and	Cancer	Progression.	
Cancer	Microenviron	Off	J	Int	Cancer	Microenviron	Soc.	2012	Dec;5(3):311–22.		
	
	 	
22	
	
	
	
Table	I.	Clinical	characteristics	of	cases	and	controls	used	in	this	study.	
Region	of	origin	 Germany	 Greece	 Italy	 Poland	 United	Kingdom	
Total	
subjects*	
Median	age	at		
diagnosis†,	y		
(1st-3rd	quartile)		
51	
(44-58)	
45	
(35-58)	
61	
(49-72)	
46	
(31-66)	
66	
(59-74)	
57	
(44-67)	
	≤50	y	 383	 151	 491	 237	 15	 1277	
	>50	y	 394	 75	 1238	 185	 209	 2101	
Gender	
	Males		 356	 135	 1098	 185	 130	 1906	
	Females	 421	 95	 814	 257	 94	 1681	
Functional	status		
	yes	 4	 20	 47	 3	 3	 77	
	no	 n/a	 2	 118	 3	 n/a	 123	
unknown	 31	 0	 82	 9	 47	 169	
Grade,	G	(WHO)	
	G1	and	G2	 n/a	 21	 149	 9	 29	 208	
	G3	 n/a	 1	 6	 2	 1	 10	
unknown	 35	 0	 12	 4	 20	 71	
Stage	(ENETS)	
	I	/	II	/	III	 17	 n/a	 133	 12	 n/a	 162	
	IV	 5	 n/a	 32	 2	 n/a	 39	
unknown	 13	 22	 82	 1	 50	 168	
Total	cases	 35	 22	 247	 15	 50	 369	
Total	controls	 797	 208	 1670	 427	 175	 3277	
Abbreviations:	WHO	=	World	Health	Organization;	ENETS	=	European	Neuroendocrine	Tumor	Society;	y	
=	years;	n/a	=	not	available	
*	Numbers	may	not	add	up	to	100%	due	to	genotyping	failure	or	unavailable	covariate	data.	
†	pNEN	cases	only
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Table	II.	Associations	between	known	GWAS	PDAC	susceptibility	loci	and	pNEN	risk.	
SNP	(nearby	gene(s))	 Genotypes	(cases/controlsa)	
MAF	CEU	
1KG	/	Current	
studyb	
MM	vs	Mmc	 MM	vs	mmc	
OR	
(95%	CI)	d	 P	
OR	
(95%	CI)	d	 P	
rs351365	(WNT2B)	
CC	(198/1549)	
CT	(108/938)	
TT	(26/172)	
0.27/0.24	 0.91	(0.69-1.20)	 0.50	
1.34	
(0.82-2.18)	 0.24	
rs3790844	(NR5A2)	
TT	(140/1231)	
TC	(64/721)	
CC	(19/123)	
0.36/0.23	 0.82	(0.59-1.13)	 0.22	
1.27	
(0.74-2.16)	 0.38	
rs1486134	(ETAA1)	
TT	(162/1569)	
TG	(141/1120)	
GG	(31/217)	
0.27/0.27	 1.20	(0.94-1.55)	 0.13	
1.36	
(0.88-2.09)	 0.16	
rs9854771	(TP63)	
GG	(149/1131)	
GA	(140/1311)	
AA	(51/350)	
0.29/0.36	 0.76	(0.58-0.99)	 0.04	
1.00	
(0.69-1.46)	 0.98	
rs2736098	(TERT)	
GG	(158/1514)	
GA	(130/1131)	
AA	(19/211)	
0.27/0.27	 1.08	(0.84-1.39)	 0.56	
0.84	
(0.50-1.41)	 0.51	
rs17688601	(SUGCT)	
AA	(31/226)	
AC	(130/1082)	
CC	(176/1469)	
0.17/0.28	 0.98	(0.77-1.26)	 0.89	
1.19	
(0.78-1.82)	 0.41	
rs6971499	(LINC-PINT)	
AA	(241/2222)	
AG	(67/755)	
GG	(5/72)	
0.12/0.15	 0.85	(0.64-1.14)	 0.27	
0.89	
(0.35-2.27)	 0.81	
rs167020	(SHH)	
AA	(20/80)	
AG	(108/392)	
GG	(127/507)	
0.15/0.26	 1.04	(0.68-1.59)	 0.85	
0.92	
(0.44-1.94)	 0.83	
rs1561927	(MIR1208,	PVT1)	
CC	(25/238)	
CT	(104/1297)	
TT	(181/1643)	
0.30/0.28	 0.71	(0.55-0.92)	 0.01	
0.91	
(0.58-1.43)	 0.69	
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SNP	(nearby	gene(s))	 Genotypes	(cases/controlsa)	
MAF	CEU	
1KG	/	Current	
studyb	
MM	vs	Mmc	 MM	vs	mmc	
OR	
(95%	CI)	d	 P	
OR	
(95%	CI)	d	 P	
rs10991043	(SMC2)	
CC	(48/371)	
CT	(146/1295)	
TT	(133/1190)	
0.43/0.36	 1.02	(0.79-1.31)	 0.90	
1.17	
(0.81-1.68)	 0.41	
rs505922	(ABO)	
TT	(110/935)	
TC	(120/1019)	
CC	(28/333)	
0.35/0.39	 1.11	(0.84-1.48)	 0.45	
0.76	
(0.48-1.19)	 0.23	
rs7310409	(HNF1A)	
GG	(120/1008)	
GA	(159/1409)	
AA	(59/490)	
0.41/0.39	 0.90	(0.69-1.16)	 0.41	
1.04	
(0.74-1.46)	 0.84	
rs9581943	(PDX1)	
GG	(110/1016)	
GA	(149/1524)	
AA	(51/510)	
0.33/0.42	 0.94	(0.72-1.22)	 0.64	
0.91	
(0.64-1.31)	 0.62	
rs9543325	
(KLF5/KLF12/PIBF1/DIS3/BORA)	
CC	(48/316)	
CT	(113/960)	
TT	(62/771)	
0.46/0.39	 1.35	(0.96-1.89)	 0.08	
1.63	
(1.10-2.47)	 0.02	
rs8028529	(None)	
TT	(155/1194)	
TC	(86/654)	
CC	(16/106)	
0.20/0.22	 1.08	(0.79-1.48)	 0.64	
1.25	
(0.69-2.25)	 0.46	
rs7190458	
(BCAR1/CTRB1/CTRB2)	
CC	(294/2832)	
CT	(18/215)	
TT	(1/5)	
0.10/0.04	 0.78	(0.46-1.30)	 0.34	
2.25	
(0.25-20.3)	 0.47	
rs11655237	(LINC00673)	
CC	(256/2113)	
CT	(75/583)	
TT	(3/37)	
0.23/0.12	 1.08	(0.80-1.45)	 0.63	
0.70	
(0.16-3.02)	 0.64	
rs1517037	(GRP)	
CC	(227/1871)	
CT	(107/896)	
TT	(10/129)	
0.24/0.20	 0.89	(0.69-1.15)	 0.36	
0.59	
(0.30-1.15)	 0.12	
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SNP	(nearby	gene(s))	 Genotypes	(cases/controlsa)	
MAF	CEU	
1KG	/	Current	
studyb	
MM	vs	Mmc	 MM	vs	mmc	
OR	
(95%	CI)	d	 P	
OR	
(95%	CI)	d	 P	
rs16986825	(ZNRF3)	
CC	(193/1996)	
CT	(100/919)	
TT	(15/108)	
0.20/0.19	 1.07	(0.82-1.39)	 0.63	
1.21	
(0.67-2.17)	 0.53	
rs2853677	(TERT)	
AA	(89/783)	
AG	(155/1319)	
GG	(52/532)	
0.39/0.45	 1.01	(0.74-1.38)	 0.94	
0.82	
(0.54-1.22)	 0.32	
rs401681	(TERT)	
TT	(51/377)	
TC	(129/949)	
CC	(76/649)	
0.41/0.43	 1.10	(0.81-1.52)	 0.52	
1.11	
(0.75-1.63)	 0.61	
rs10919791	(NR5A2)	
GG	(148/1272)	
GA	(50/682)	
AA	(15/111)	
0.35/0.22	 0.65	(0.46-0.93)	 0.02	
1.06	
(0.59-1.90)	 0.84	
rs3790843	(NR5A2)	
GG	(124/1064)	
GA	(72/847)	
AA	(25/178)	
0.40/0.29	 0.76	(0.55-1.04)	 0.09	
1.20	
(0.74-1.93)	 0.46	
Abbreviations:	MAF	CEU	=	minor	allele	 frequency	 in	Caucasians;	1kG	=	1000	Genomes	Project	 (http://browser.1000genomes.org);	OR	=	odds	
ratio;	CI	=	confidence	interval.		
Only	association	results	for	SNPs	with	P<0.05	and	with	outcomes	below	FPRP-level	0.2	are	marked	bold.	
a	Numbers	may	not	add	up	to	100%	due	to	genotyping	failure	or	unavailable	covariate	data;	b	Controls	only;	c	M	-	major	allele,	m	-	minor	allele	
where	MM	represents	the	reference	category.		
d	Analyses	were	performed	with	adjustment	for	age,	gender	and	country	of	origin.
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Table	III.	Associations	between	TERT_rs2736098,	ZNF_rs16986825,	rs9543325	and	risk	of	pNEN	
onset.	
Locus	 Gene	 SNP	ID	 Genotypes	(Cases≤50y/>50y)	 OR	(95%	CI)
a	 P	
5p15.33	 TERT	 rs2736098	
GG	(52/104)	
GA	(36/89)	
AA	(12/7)	
0.83	(0.50-1.40)†	
3.71	(1.36-10.10)*	
1.04	(0.64-1.69)¥	
0.49	
0.01	
0.89	
22q12.1	 ZNRF3	 rs16986825	
CC	(53/136)	
CT	(46/52)	
TT	(3/11)	
2.67	(1.57-4.55)†	
0.67	(0.17-2.63)*	
2.27	(1.37-3.77)¥	
0.0003	
0.57	
0.002	
3q28	 TP63	 rs9854771	
GG	(38/108)	
GA	(53/87)	
AA	(15/35)	
1.85	(1.11-3.10)†	
1.29	(0.63-2.66)*	
1.69	(1.04-2.75)¥	
0.02	
0.49	
0.03	
Only	association	results	for	SNPs	with	P<0.05	and	with	outcomes	below	FPRP-level	0.2	are	marked	bold.	
a	Cases	only	-	≤50	years	(n=114)	versus	>50	years	(n=247);	where	cases	>50	years	represent	the	
reference	category.	Analyses	were	performed	with	adjustment	for	gender	and	country	of	origin.	
†	MM	vs	Mm;	*	MM	vs	mm;	¥	(MM+Mm)	vs	mm;	where	M	-	major	allele	and	m	-	minor	allele;	y=	years.	
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Table	IV.	Associations	between	SNPs	and	pNEN	tumor	characteristics.	
Locus	 Gene	 SNP	 Genotype	groups	 OR	(95%	CI)a	 P	
Grade	(G1/G2/well	differentiated	tumors	vs.	G3/poorly	differentiated	tumors)	
1q32.1	 NR5A2	 rs10919791	 GG/GA/AA	115/38/15	 5.66	(1.18-27.11)†	 0.03	
22q12.1	 ZNRF3	 rs16986825	 CC/CT/TT		113/62/9	
7.34	(1.02-52.67)*	
	7.44	(1.10-50.53)¥	
0.05	
0.04	
Stage	(I/II/III	vs.	IV)	
8q24.21	 MIR1208,	PVT1	 rs1561927	 CC/TC/TT	18/55/95	 2.39	(1.18-4.85)†	 0.02	
3q28	 TP63	 rs9854771	 AA/GA/GG	22/67/81	 0.44	(0.22-0.90)†	 0.02	
1p13.1	 WNT2B	 rs351365	 AA/GA/GG	11/58/99	
4.15	(1.01-16.95)*	
4.62	(1.16-18.38)¥	
0.05	
0.03	
Functional	status	(functional	tumors	vs.	non-functional	tumors)	
12q24.21	 HNF1A	 rs7310409	 AA/GA/GG	32/79/66	 0.36	(0.16-0.79)†	 0.01	
18q21.2	 GRP	 rs1517037	 CC/CT/TT	118/56/4	 0.37	(0.16-0.85)†	 0.02	
Only	association	results	for	SNPs	with	P<0.05	and	with	outcomes	below	FPRP-level	0.2	are	marked	bold.	
Analyses	were	performed	with	adjustment	for	age,	gender	and	country	of	origin.	
a	All	G1	and	G2	(i.e	well-differentiated)	tumors,	non-functional	tumors,	and	Stage	I,	II	and	III	tumors	(i.e.	
no	nodal	metastasis)	represent	the	reference	category	for	Grade,	Functional	status	and	Stage	
respectively.	†	MM	vs	Mm;	*	MM	vs	mm;	¥	(MM+Mm)	vs	mm;	where	M	-	major	allele	and	m	-	minor	
allele	
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Table	V.	Differentially-expressed	genes	obtained	from	the	GSE43795	dataset	(6	pNEN	tumors	vs.	5	non-neoplastic	pancreatic	tissue	
samples	and	6	pNEN	tumors	vs.	6	ductal	adenocarcinoma	tissues).	
Gene	
pNEN	vs.	normal	 PDAC	vs.	normal	
Log2	fold-change	 P	 Adjusted-P*	 Log2	fold-change	 P	 Adjusted-P*	
MYC	 4.38	 9.47x10-7	 5.88x10-5	 2.65	 4.55x10-4	 5.93x10-3	
NR5A2	 4.91	 7.82x10-10	 2.38x10-7	 3.51	 2.00x10-4	 3.31x10-3	
KLF5	 1.69	 1.59x10-2	 6.96x10-2	 -1.41	 1.59x10-1	 3.18x10-1	
CTRB1	 7.90	 1.10x10-9	 3.04x10-7	 7.55	 2.56x10-8	 5.18x10-6	
CTRB2	 7.70	 6.75x10-8	 8.08x10-6	 7.33	 1.71x10-6	 1.13x10-4	
PDX1	 0.72	 3.58x10-1	 5.49x10-1	 2.43	 1.18x10-3	 1.16x10-2	
*	P-value	adjusted	using	Benjamini	&	Hochberg	method	(False	discovery	rate)	
Based	on	predefined	cutoff	value	of	Adjusted-P	<	0.05	and	|log2	fold-change|	>	1,	genes	which	are	differentially	expressed	in	both	groups	are	in	
bold.	
	
